Vertex Pharmaceuticals Inc / Ma (VRTX) · Aug 3, 2026 · Earnings

Revenue beat and guidance rose, but adjusted EPS missed expectations

Beat — Revenue $3.33B vs ~$3.23B consensus; FY revenue guide raised to $13.1B-$13.2B

Revenue beat and guidance rose, but adjusted EPS missed expectations

The quarter cleared the market’s top-line bar, but not its profit bar. Published expectations were roughly $3.23 billion of revenue and $4.85 of adjusted diluted EPS; Vertex delivered $3.33 billion and $4.73, respectively. Revenue therefore beat by about 3%, while adjusted EPS missed by roughly 2.5% as operating investment increased. (Financial Highlights)

MetricQ2 2026Q2 2025Market expectation
Total revenue$3.334B (Financial Highlights)$2.965B (Financial Highlights)~$3.23B
Non-GAAP diluted EPS$4.73 (Non-GAAP reconciliation)$4.52 (Non-GAAP reconciliation)~$4.85
GAAP diluted EPS$4.31 (Income Statement)$3.99 (Income Statement)—
JOURNAVX revenue$49.6M (Product revenues by product)$12.0M (Product revenues by product)—
TRIKAFTA/KAFTRIO revenue$2.497B (Product revenues by product)$2.551B (Product revenues by product)—

Growth is broadening beyond the mature CF base. Total revenue rose 12% year over year, with ALYFTREK revenue reaching $573.6 million versus $156.8 million a year earlier, JOURNAVX more than quadrupling to $49.6 million, and CASGEVY rising to $76.4 million. (Product revenues by product) That diversification helped offset a 2% decline in TRIKAFTA/KAFTRIO revenue, which remains the largest product line.

Management raised the revenue outlook, which is the clearest upside signal in the filing. Full-year revenue guidance moved from $12.95-$13.1 billion to $13.1-$13.2 billion, while expense and tax guidance were unchanged. (Full Year 2026 Financial Guidance) The increase is modest—only about $125 million at the midpoint—and still includes roughly 150 basis points of foreign-exchange benefit, so it is an improvement rather than a major reset.

The trade-off is heavier spending and a pending acquisition that remains outside the outlook. Combined non-GAAP R&D, acquired IPR&D and SG&A rose to $1.43 billion from $1.24 billion, driven by JOURNAVX commercialization and the renal franchise build-out. (Non-GAAP expense reconciliation) The $10 billion Crinetics acquisition is expected to close in Q3 2026, after which Vertex says it will update guidance; that refreshed outlook and early evidence on the acquired endocrine portfolio are the next material tests. (Acquisition announcement)

What to watch next

Crinetics closing and refreshed 2026 guidance in Q3

Original filing on SEC EDGAR

More Vertex Pharmaceuticals Inc / Ma news

Revenue beat and guidance rose, but adjusted EPS missed expectations | VRTX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.